Based on these findings, pembrolizumab was approved by the FDA on 26 January 2023, for use as an adjuvant therapy following surgery and platinum-based chemotherapy for patients with stage IB–IIIA NSCLC, regardless of PD-L1 expression [36]. Here, CD274 is linked to non-small cell lung carcinoma.